Reaxa Recieves Grant To Scale-UP Ni EnCat

UK-based Reaxa has received research and development grant from the Northwest Regional Development Agency (NWDA). The fund for R&D amounts to £146K (E164K). The grant is expected to scale up production of EnCat nickel catalyst.

Reportedly, the technology encases nickel hydrogenation catalyst in a polymeric matrix designed, which reduces degradation, enable improved recycling, and prevent leeching in processing.

The grant will fund development for 18 months and will also support regulatory filing, reported in-pharma.

Mark Hughes, agency executive director, said: “Reaxa has already demonstrated its technical expertise and added that he is confident the new project will advance a technology for which there will be strong market demand.

“The pharmaceutical and fine chemicals industry is looking for a product such as Reaxa’s new EnCat catalyst, and we are delighted to be able to support scale up.”